Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent? - Endpoints News

Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent?  Endpoints News